期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Ad5F35-LMP2重组腺病毒免疫效果的研究 被引量：2

Immune responses induced by recombinant adenovirus AdSF35-LMP2 in rhesus monkeys
原文传递
导出
摘要 目的了解含有EB病毒潜伏膜蛋白2的非复制型重组腺病毒（Ad5F35-LMP2），免疫恒河猴的特异性细胞和体液免疫的效果。方法分别使用高剂量（1．5×10^10TCID50/只）、中剂量（1．5×10^9TCID50/只）、低剂量（1．5×10^8TCID50/只）Ad5F35-LMP2重组腺病毒，同时设对照组（PBS4．0 ml／只）。肌内注射免疫恒河猴，每个月一次，共免疫3次，第0、4、8、12周时使用Elispot方法检测猴外周血EBV—LMP2细胞毒性T细胞应答，同时应用免疫酶方法检测血清中LMP2抗体。结果3个剂量Ad5F35-LMP2腺病毒免疫恒河猴均可以诱导出有效的细胞免疫应答及一定的抗体应答，免疫应答水平的高低与病毒剂量的高低有一定的关系，较高剂量产生的细胞及体液免疫应答水平比低剂量的高。结论Ad5F35-LMP2非复制型重组腺病毒疫苗可以有效的诱导恒河猴产生EBV—LMP2特异性细胞和体液免疫反应。 Objective To observe the specific cellular and humoral immune responses after immunization with recombinant adenovirus AdSF35-LMP2 in rhesus monkeys. Methods Sixteen rhesuses were immunized with AdSF35-LMP2 through intra-muscular injection in three groups, high dosage group （1.5 × 10^10 TCID50/rhesus）, medium dosage group （1.5 × 10^9 TCID50/rhesus）, low dosage group （1.5 × 10^8 TCID50/rhesus） and the last group was control （PBS 4 ml/rhesus） .They were totally immunized three times at intervals of one month .The EBV-LMP2 specific cellular immune responses were tested during the 0, 4, 8, 12 weeks by Elispot after immunization respectively.And the titers of anti-LMP2 antibody were tested by EIA at the same time, Results EBV-LMP2 specific cellular and humoral immune responses which were induced by recombinant adenovirus AdSF35-LMP2 can be found in all the three dosage groups. The potency of immune responses was related with the dosage of immunization. Higher dosage elicited more potent immune response. Conclusion The recombinant adenovirus Ad5F35-LMP2 could elicit LMP2 specific cellular and humoral immune responses in rhesus.
作者 莫武宁 周玲 吴小兵 王湛 唐安洲 黄光武 余双庆 王琦 叶树清 杜海军 曾毅
机构地区 南宁广西医科大学第一附属医院 中国疾病预防控制中心病毒病所国家重点实验室
出处 《中华实验和临床病毒学杂志》 CAS CSCD 北大核心 2007年第3期226-228,共3页 Chinese Journal of Experimental and Clinical Virology
基金 国家“863”重大资助项目（2006AA02A229） 国家“973”资助项目（2004C8518806）
关键词 重组 遗传 腺病毒 人 疱疹病毒4型 人 膜蛋白质类 恒河猴 免疫 细胞 Recombination, genetic Adenoviruses, humam Herpesvirus 4, human Membranceproteins Macaca mulatta Immunity, cellular
分类号 R3 [医药卫生—基础医学]
  • 相关文献

参考文献7

  • 1Lee SP, Chan AT, Cheung ST, et al. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells. J Immunol, 2000, 165:573-582.
  • 2周玲,姚庆云,Steve.Lee,A.Rickinson,曾毅.鼻咽癌病人和正常人群中EB病毒特异性T细胞对靶抗原的识别和应答[J].病毒学报,2001,17(1):7-10. 被引量：13
  • 3Sing AP, Ambinder RF, Hong DJ. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-steinberg cells: Implications for immune-mediated therapy of EBV-Hodgkin's disease. Blood, 1997, 89 : 1978-1986.
  • 4Straathof KC, Bollard CM, Popat U, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood, 2005,105 :1898-1904.
  • 5Havenga MJ, Lemckert AA, Ophorst O J, et al. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J Virol, 2002,76:4612-4620.
  • 6Yotnda P, Onishi H, Heslop H E, et al. Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther, 2001; 8:930-937.
  • 7莫武宁,周玲,吴小兵,王湛,唐安洲,黄光武,曾毅.Ad5F35-LMP2重组腺病毒的构建及鉴定[J].中国免疫学杂志,2007,23(3):251-255. 被引量：4

二级参考文献18

  • 1林毓纯 商铭 等.鼻咽癌的细胞免疫及其HLA的限制[J].病毒学报,1982,4(4):254-256.
  • 2周玲，中华实验和临床簿学杂志，2000年，14卷，4期，384页
  • 3林毓纯，病毒学报，1982年，4卷，4期，254页
  • 4Mann K P,Thorley L D.Posttranslation processing of the Epstein-Barr virus-encoded P63/LMP protein[J].J Virol,1987; 61:2100-2108.
  • 5Wang D,Liebowitz B,Kieff.An EBV membrane protein expressed in immuortalized lymphocytes transforms established rodent cells[J].Cell,1986; 43:831-840.
  • 6Bollard C M,Straathof K C M,Huls M H et al.The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive hodgkin disease[J].J Immunother,2004;27:317-327.
  • 7Lee S P,Chan A T,Cheung S T et al.CTL control of EBV in nasopharyngeal carcinoma(NPC):EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells[J].J Immunol,2000;165(1):573-582.
  • 8Sing A P,Ambinder R F,Hong D J.Isolation of Epstein-Barr virus(EBV)-specific cytotoxic T lymphocytes that lyse Reed-sternberg cells:implications for immune-mediated therapy of EBV-Hodgkin's disease[J].Blood,1997; 89(6):1978-1986.
  • 9Savoldo B,Huls M H,Liu Z et al.autologous EBV-specific cytotoxic T cells for the treatment of persistent active EBV infection[J].Blood,2002; 100(12):4059-4066.
  • 10Straathof K C,Bollard C M,Popat U et al.Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes[J].Blood,2005;105(5):1898-1904.

共引文献14

同被引文献19

  • 1王湛,周玲,吴小兵,卢觅佳,宣尧仙,左建民,李峰,王琦,叶树清,曾毅.Ad-LMP2重组腺病毒疫苗在恒河猴体内免疫效果的研究[J].中华实验和临床病毒学杂志,2006,20(2):63-65. 被引量：6
  • 2莫武宁,周玲,吴小兵,王湛,唐安洲,黄光武,曾毅.Ad5F35-LMP2重组腺病毒的构建及鉴定[J].中国免疫学杂志,2007,23(3):251-255. 被引量：4
  • 3Havenga M J, Lemckert AA, Ophorst O J, et al. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J Virol, 2002,76: 4612-4620.
  • 4Yotnda P, Onishi H, Heslop H E, et al. Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther, 2001,8: 930-937.
  • 5Steinman RM,Cohn ZA.Identification of a novel cell type inperipheral lymphoid organs of mice I Morphology quantitationtissue distribution[J].J Exp Med,1973,11(37):1142-1162.
  • 6Steinman RM.The dendritic cell system and its role in immunoge-nicity[J].Annu Rev Immunol,1991,l9(2):271-296.
  • 7Nestle FO,Alijagic S,Gilliet M.tumor lysate-pulsed dendritic cells[J].Nat Med,1998,4(3):328-332.
  • 8O’Rourke MG,Johnson MK,Lanaqan CM,et al.Dendritic cellimmunotherapy for stageⅣmelanoma[J].Melanoma Res,2007,17(5):316-322.
  • 9Fong L,Brockstedt D,Benike C,et al.Dendritic cell-based xenoanti-gen vaccination for prostate cancer immunotherapy[J].J Immunol,2001,67(12):7150-7156.
  • 10Yamaquchi Y,Ohta K,Kawabuchi Y,et al.Feasibility study ofadoptive immunotherapy dendritic cell-activated killer(PDAK)cells[J].Anticancer Res,2005,l25(3c):2407-2415.

引证文献2

二级引证文献3

中华实验和临床病毒学杂志
2007年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部